Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.11.1.7 (peroxidase)
 65,474 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Monoclonal antibody MT2 and anti-immunoglobulins were tested for their ability to discriminate between reactive lymphoid hyperplasia and follicular lymphoma (centroblastic/centrocytic; CB/CC) informalin-fixed and wax-embedded biopsies. The streptavidin biotin peroxidase complex method was used. In 46 of 49 cases of reactive follicular hyperplasia the follicle center cells were unstained by MT2 whereas the mantle zone B cells and interfollicular T cells were positive. In three reactive cases up to 30% of follicle center cells also were stained. In contrast, more than 50% of neoplastic follicle center cells were stained by MT2 in 27 of 62 cases of CB/CC, and light chain restriction was shown in 52 of 62 cases. MT2 staining and/or light chain restriction was seen in 57 of 62 cases. In 106 further cases of non-Hodgkin's lymphoma, MT2 was positive in 59 of 77 B cell lymphomas and 3 of 29 T cell lymphomas. Although not a B cell specific reagent, MT2 is useful in the differential diagnosis of reactive vs. neoplastic follicular lymphoid proliferations but is less sensitive than immunoglobulin stains.
 ...
PMID:A comparison between monoclonal antibody MT2 and immunoglobulin staining in the differential diagnosis of follicular lymphoid proliferations in routinely fixed wax-embedded biopsies. 246 83

A sandwich-type ELISA has been developed for quantification of the complex between the cysteine proteinase cathepsin B (CB) and its reversible tight-binding inhibitor cystatin C (CC) in normal and pathological sera. The assay is based on a combination of catching Ab (3E1), raised against CB, and a horseradish peroxidase-labelled detection Ab (1A2), raised against CC. Only the CB/CC complex is able to evoke a signal in this assay. The detection limit of the assay was 15.5 nM and the working range between 31.3-200 nM. The within and between-run coefficients of variance (CV) varied from 4.7% to 9.4% and 11% to 12.8%, respectively, demonstrating satisfactory reproducibility of the method. The concentration of the CB/CC complex was determined in sera from 90 healthy controls, 32 patients with non-cancerous lung diseases, 148 patients with lung and 32 patients with colorectal cancer. The CB/CC complex was significantly less abundant in sera of patients bearing malignant lung tumours than in those with non-cancerous lung diseases or healthy controls (p<0.001). In colorectal cancer sera its level was significantly lower in advanced stages C and D than in early Dukes' stages A and B (p=0.02). Our results show that the increased levels of CB in malignant sera are not impaired effectively by CC and support the hypothesis of hindered inhibitory capability during cancer progression.
 ...
PMID:Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer. 1151 34